Parkinson's investigational therapy update highlighting trial progress and company plans. Expect an upbeat look at study conduct, oversight and next development steps.
Key Takeaways
- Sentinel dosing in Cohort 1 completed and SMC recommended continued dosing
- Cohort 1 enrollment is expected to finish ahead of prior third quarter 2026 guidance
- Randomized double-blind placebo-controlled study uses ascending-dose cohorts and exploratory motor outcomes